


Amendments to the Claims


This Listing of the Claims will replace all prior versions, and listings, of claims in the application.

Listing of the Claims:

1. (Currently Amended) A compound of formula I



~~Wherein~~ wherein



~~R<sub>1</sub> is selected from a)~~

R<sub>2</sub> is lower alkyl or hydrogen;

R<sub>3</sub> is ~~OH~~ or hydrogen;


Z is O, C or -Z- is a bond between the two binding carbon atoms;

~~.....~~ is a single or double bond between C2 and C3;

or salts thereof;

~~with the proviso that when R<sub>1</sub> is a, R<sub>3</sub> is hydrogen and that when R<sub>1</sub> is b, Z is O or a bond, and R<sub>2</sub> is methyl R<sub>3</sub> is not OH.~~

2. (Currently Amended) A The compound of formula I according to claim 1, wherein




R<sub>1</sub> is

R<sub>2</sub> is lower alkyl; preferably methyl

R<sub>3</sub> is hydrogen;

Z is O or -Z- is a bond between the two binding carbon atoms;

 is a single bond;  
or salts thereof.

3. (Cancelled).

4. (Currently Amended) The compound of formula I according to claim 1 selected from the group consisting of,

(Z)-(7R,8S,9S,16S)-8-Hydroxy-5,5,7,9,13-pentamethyl-16-[(E)-1-methyl-2-(2-methyl-thiazol-4-yl)-vinyl]-oxacyclohexadec-13-ene-2,6-dione; and

(1S,3S,10R,11S,12S,16R)-11-Hydroxy-8,8,10,12,16-pentamethyl-3-[(E)-1-methyl-2-(2-methyl-thiazol-4-yl)-vinyl]-4,17-dioxo-bicyclo[14.1.0]heptadecane-5,9-dione;

~~16-(1,2-Dimethyl-1H-benzoimidazol-5-yl)-8-hydroxy-5,5,7,9-tetramethyl-oxacyclohexadec-13-ene-2,6-dione;~~

~~3-(1,2-Dimethyl-1H-benzoimidazol-5-yl)-11-hydroxy-8,8,10,12-tetramethyl-4,17-dioxo-bicyclo[14.1.0]heptadecane-5,9-dione;~~

~~(Z)-(7R,8S,9S,16S)-16-(1,2-Dimethyl-1H-benzoimidazol-5-yl)-8-hydroxy-5,5,7,9,13-pentamethyl-oxacyclohexadec-13-ene-2,6-dione;~~

~~(1S,3S,10R,11S,12S,16R)-3-(1,2-Dimethyl-1H-benzoimidazol-5-yl)-11-hydroxy-8,8,10,12,16-pentamethyl-4,17-dioxo-bicyclo[14.1.0]heptadecane-5,9-dione;~~

~~(E)-(7R,8S,9S,16S)-16-(1,2-Dimethyl-1H-benzoimidazol-5-yl)-8-hydroxy-5,5,7,9-tetramethyl-oxacyclohexadec-13-ene-2,6-dione;~~

~~(1S,3S,10R,11S,12S,16S)-3-(1,2-Dimethyl-1H-benzoimidazol-5-yl)-11-hydroxy-8,8,10,12-tetramethyl-4,17-dioxo-bicyclo[14.1.0]heptadecane-5,9-dione;~~

~~16-(1,2-Dimethyl-1H-benzoimidazol-5-yl)-4,8-dihydroxy-5,5,7,9-tetramethyl-oxacyclohexadec-13-ene-2,6-dione;~~

~~3-(1,2-Dimethyl-1H-benzoimidazol-5-yl)-7,11-dihydroxy-8,8,10,12-tetramethyl-4,17-dioxo-bicyclo[14.1.0]heptadecane-5,9-dione;~~

~~(E)-(4S,7R,8S,9S,16S)-16-(1,2-Dimethyl-1H-benzoimidazol-5-yl)-4,8-dihydroxy-5,5,7,9-tetramethyl-oxacyclohexadec-13-ene-2,6-dione;~~

~~(1S,3S,7S,10R,11S,12S,16S)-3-(1,2-Dimethyl-1H-benzoimidazol-5-yl)-7,11-dihydroxy-8,8,10,12-tetramethyl-4,17-dioxo-bicyclo[14.1.0]heptadecane-5,9-dione;~~

~~(3E,13E) (7R,8S,9S,16S) 16-(1,2-Dimethyl-1H-benzoimidazol-5-yl)-8-hydroxy-5,5,7,9-tetramethyl-oxacyclohexadeca-3,13-diene-2,6-dione;~~

~~(E) (1S,3S,10R,11S,12S,16S) 3-(1,2-Dimethyl-1H-benzoimidazol-5-yl)-11-hydroxy-8,8,10,12-tetramethyl-4,17-dioxo-bicyclo[14.1.0]heptadec-6-ene-5,9-dione;~~

~~3-(1,2-Dimethyl-1H-benzoimidazol-5-yl)-7,11-dihydroxy-8,8,10,12-tetramethyl-4-oxa-bicyclo[14.1.0]heptadecane-5,9-dione; and~~

~~(1S,3S,7S,10R,11S,12S,16R) 3-(1,2-Dimethyl-1H-benzoimidazol-5-yl)-7,11-dihydroxy-8,8,10,12-tetramethyl-4-oxa-bicyclo[14.1.0]heptadecane-5,9-dione~~

5. (Previously Presented) A pharmaceutical composition comprising the compound of formula I according to claim 1, or a salt thereof, provided that salt-forming groups are present, and one or more pharmaceutically acceptable carriers.

6.-9. (Cancelled).